IND vs CTA: a practical map for regulatory associates

Two gates, one goal Both an Investigational New Drug (IND) application and a Clinical Trial Application (CTA) exist to ensure a trial can start with acceptable quality and patient safety. The paths differ by agency, format, and timing expectations.

IND (United States — FDA) When: Before first-in-human or other US clinical studies of an unapproved drug (with exceptions for certain legally marketed drugs in specific contexts). Core content: Chemistry/manufacturing, pharmacology/toxicology, clinical protocol, investigator brochure, and supporting stability or analytical data as applicable. Mindset: Structured submission under 21 CFR 312 expectations; communication with the review division is part of the workflow. CTA / IMPD cluster (European Union) When: Before starting a clinical trial in EU member states under CTR (EU) 536/2014 (replacing the older national directives regime for new trials). Core content: Protocol, investigator’s brochure, IMPD (investigational medicinal product dossier), and supporting safety and quality documentation; national particulars may still matter for certain operational aspects during transition. Mindset: One EU portal process with Part I (scientific) and Part II (national/ethics) considerations. How associates add value Map submission calendars, own query responses, track labeling alignment between IB and protocol, and maintain traceability from source data to CSR-ready tables. That is the work hiring managers want to see on day one.

This article ships with the site; replace it by publishing a post with the same slug in the learning studio.